![]() | |
Clinical data | |
---|---|
Trade names | Vonjo |
Other names | SB1518 |
License data |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C28H32N4O3 |
Molar mass | 472.589 g·mol−1 |
3D model ( JSmol) | |
| |
|
Pacritinib, sold under the brand name Vonjo, is an anti-cancer medication used to treat myelofibrosis. [1] [2] It is a macrocyclic protein kinase inhibitor. It mainly inhibits Janus kinase 2 (JAK2) and Fms-like tyrosine kinase 3\CD135 (FLT3).
Common side effects include diarrhea, low platelet counts, nausea, anemia, and swelling in legs. [2]
Pacritinib in indicated to treat adults who have a rare form of a bone marrow disorder known as intermediate or high-risk primary or secondary myelofibrosis and who have platelet (blood clotting cells) levels below 50,000/μL. [1] [2]
The effectiveness and safety of pacritinib were demonstrated in a study that included 63 participants with intermediate or high-risk primary or secondary myelofibrosis and low platelets who received pacritinib 200 mg twice daily or standard treatment. [2] Effectiveness was determined based upon the proportion of participants who had a 35% or greater spleen volume reduction from baseline to week 24. [2] Nine participants (29%) in the pacritinib treatment group had a 35% or greater spleen volume reduction, compared to one participant (3%) in the standard treatment group. [2]
The U.S. Food and Drug Administration (FDA) granted the application for pacritinib priority review, fast track, and orphan drug designations. [2]
Pacritinib is the International nonproprietary name (INN). [3] [4]
![]() | |
Clinical data | |
---|---|
Trade names | Vonjo |
Other names | SB1518 |
License data |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C28H32N4O3 |
Molar mass | 472.589 g·mol−1 |
3D model ( JSmol) | |
| |
|
Pacritinib, sold under the brand name Vonjo, is an anti-cancer medication used to treat myelofibrosis. [1] [2] It is a macrocyclic protein kinase inhibitor. It mainly inhibits Janus kinase 2 (JAK2) and Fms-like tyrosine kinase 3\CD135 (FLT3).
Common side effects include diarrhea, low platelet counts, nausea, anemia, and swelling in legs. [2]
Pacritinib in indicated to treat adults who have a rare form of a bone marrow disorder known as intermediate or high-risk primary or secondary myelofibrosis and who have platelet (blood clotting cells) levels below 50,000/μL. [1] [2]
The effectiveness and safety of pacritinib were demonstrated in a study that included 63 participants with intermediate or high-risk primary or secondary myelofibrosis and low platelets who received pacritinib 200 mg twice daily or standard treatment. [2] Effectiveness was determined based upon the proportion of participants who had a 35% or greater spleen volume reduction from baseline to week 24. [2] Nine participants (29%) in the pacritinib treatment group had a 35% or greater spleen volume reduction, compared to one participant (3%) in the standard treatment group. [2]
The U.S. Food and Drug Administration (FDA) granted the application for pacritinib priority review, fast track, and orphan drug designations. [2]
Pacritinib is the International nonproprietary name (INN). [3] [4]